Sales of migraine drug exceed expectations at Lundbeck during third quarter

The third quarter financial results at Lundbeck were more or less as expected, though one high point was miraine drug Vyepti, where sales surpassed analysts' expectations. The company is turning up the heat on the US market as it looks to the future.

Photo: Thomas Borberg

There were no surprises in Lundbeck's Q3 report released on Wednesday morning. The company has more or less performed as it expected to – exceeding some targets, meeting some exactly, and narrowly missing others.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs